Gupta C K, Leszczynski J, Gupta R K, Siber G R
Massachusetts Public Health Biologic Laboratories, Boston 02130, USA.
Biologicals. 1996 Jun;24(2):117-24. doi: 10.1006/biol.1996.0015.
An enzyme-linked immunoabsorbent assay (ELISA) was developed for quantitation of IgG subclass antibodies to human cytomegalovirus (CMV) in human serum or plasma samples and in immune globulin (IG) preparations. The assay was based on the parallel titration of known concentrations of purified IgG subclass myeloma proteins and a specific CMV antiserum. The purified IgG subclass myeloma proteins were captured on an ELISA plate pre-coated with anti-human kappa, anti-human lambda or a mixture of anti-human kappa and lambda antibodies and the specific antiserum was titrated against CMV antigen coated on the plate. IgG subclass antibodies, captured or bound to antigen, were quantitated with IGG subclass heavy chain specific monoclonal antibodies. The method was highly reproducible, specific and sensitive. Using this method, 257 human plasma samples and 50 IG preparations were assayed for CMV specific IgG subclass and IgM antibodies. The major IgG subclass antibody to CMV was IgG1 which represented more than 96% of CMV IgG antibodies, followed by IgG3 (mean CMV IgG3 antibody content was 3% of IgG antibodies in IG preparations and 1.8% in plasma samples). A majority of the samples had low levels of IgG2 antibodies and a few samples exhibited low levels of IgG4 antibodies. IG preparations showed very low levels of CMV IgM antibodies whereas plasma samples had 14.2% of CMV antibodies (IgG and IgM) as IgM antibodies. Virus neutralizing (Nt) activity of these samples showed a significant correlation with CMV IgG1 antibodies. Nine samples of plasma and IGs were further evaluated for Nt activity of IgG1 and IgG3 antibodies by separating IgG3 from the rest of the antibodies with protein A agarose. IgG3 antibodies showed much higher Nt activity than IgG1 antibodies suggesting that enrichment of IgG3 antibodies in IG preparations may be useful in preparing CMV specific IG.
开发了一种酶联免疫吸附测定法(ELISA),用于定量检测人血清或血浆样本以及免疫球蛋白(IG)制剂中针对人巨细胞病毒(CMV)的IgG亚类抗体。该测定法基于已知浓度的纯化IgG亚类骨髓瘤蛋白和特异性CMV抗血清的平行滴定。纯化的IgG亚类骨髓瘤蛋白被捕获在预先包被有抗人κ、抗人λ或抗人κ和λ抗体混合物的ELISA板上,特异性抗血清针对包被在板上的CMV抗原进行滴定。捕获或结合到抗原上的IgG亚类抗体用IgG亚类重链特异性单克隆抗体进行定量。该方法具有高度的可重复性、特异性和敏感性。使用该方法,对257份人血浆样本和50份IG制剂进行了CMV特异性IgG亚类和IgM抗体检测。针对CMV的主要IgG亚类抗体是IgG1,占CMV IgG抗体的96%以上,其次是IgG3(IG制剂中CMV IgG3抗体的平均含量为IgG抗体的3%,血浆样本中为1.8%)。大多数样本的IgG2抗体水平较低,少数样本的IgG4抗体水平较低。IG制剂显示出极低水平的CMV IgM抗体,而血浆样本中有14.2%的CMV抗体(IgG和IgM)为IgM抗体。这些样本的病毒中和(Nt)活性与CMV IgG1抗体呈显著相关性。通过用蛋白A琼脂糖将IgG3与其余抗体分离,对9份血浆和IG样本的IgG1和IgG3抗体的Nt活性进行了进一步评估。IgG3抗体显示出比IgG1抗体高得多的Nt活性,这表明在IG制剂中富集IgG3抗体可能有助于制备CMV特异性IG。